Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cybin Inc (CYBN)

Cybin Inc (CYBN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,034,596
  • Shares Outstanding, K 410,855
  • Annual Sales, $ 0 K
  • Annual Income, $ -57,880 K
  • 60-Month Beta 0.41
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.96
Trade CYBN with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.38
  • Number of Estimates 1
  • High Estimate -0.38
  • Low Estimate -0.38
  • Prior Year -1.52
  • Growth Rate Est. (year over year) +75.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.50 +48.92%
on 09/19/24
10.63 -8.92%
on 09/24/24
+2.08 (+27.37%)
since 09/13/24
3-Month
6.50 +48.92%
on 09/19/24
12.47 -22.38%
on 07/16/24
-2.67 (-21.60%)
since 07/15/24
52-Week
6.50 +48.92%
on 09/19/24
28.04 -65.48%
on 10/31/23
-12.22 (-55.79%)
since 10/13/23

Most Recent Stories

More News
A Swell Of Insider Purchases Follow Cybin Inc.'s Positive Year-End Update

Miami, Florida--(Newsfile Corp. - July 8, 2024) - Fast-moving sectors need equally fast-moving companies, a box that Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) checks, supported by a June 26th update...

CYBN : 9.68 (-1.43%)
CYBN.NE : 13.3400 (-0.45%)
How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition

EQNX::TICKER_START (NYSE:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(NASDAQ:ATAI) EQNX::TICKER_END

CYBN.NE : 13.3400 (-0.45%)
MMED.NE : 14.9000 (+9.48%)
CYBN : 9.68 (-1.43%)
ATAI : 1.0900 (-0.91%)
MNMD : 5.91 (+1.72%)
SEEL : 1.28 (-47.76%)
CMPS : 5.94 (-2.94%)
Breakthrough Results: Cybin's CYB003 Demonstrates Remarkable Interim Data in Treating Major Depressive Disorder, Achieving Primary Efficacy Milestone and Delivering Prompt Relief from Depression Symptoms with a Single Dose - Comprehensive Topline Data Anticipated by Q4 2023

- Interim readout shows rapid, robust, and clinically significant reduction of depression symptoms three weeks after a single 12mg dose, with an unprecedented mean -14 point Montgomery-Asberg Depression...

CYBN : 9.68 (-1.43%)
CYBN.NE : 13.3400 (-0.45%)
Demand for Abuse Deterrent Formulation Technology Skyrocketing as Opiate Abuse is on the Rise

/PRNewswire/ -- The demand for abuse deterrent formulation technology is projected to grow due to growing misuse of drugs among the people. Growing demand for...

NTRBW : 1.9600 (-2.00%)
CYBN : 9.68 (-1.43%)
NTRB : 7.58 (-6.30%)
CMND : 1.5900 (+12.77%)
MNMD : 5.91 (+1.72%)
LLY : 913.32 (-1.74%)
Demand for Abuse Deterrent Formulation Technology Skyrocketing as Opiate Abuse is on the Rise

EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:CMND),(NASDAQ:MNMD),(NYSE:CYBN),(NYSE:LLY) EQNX::TICKER_END

NTRB : 7.58 (-6.30%)
NTRBW : 1.9600 (-2.00%)
CMND : 1.5900 (+12.77%)
MNMD : 5.91 (+1.72%)
CYBN : 9.68 (-1.43%)
LLY : 913.32 (-1.74%)
Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031

EQNX::TICKER_START (NYSE:CYBN),NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(OTCQX:NUMIF) EQNX::TICKER_END

CYBN.NE : 13.3400 (-0.45%)
MMED.NE : 14.9000 (+9.48%)
CYBN : 9.68 (-1.43%)
CMPS : 5.94 (-2.94%)
SEEL : 1.28 (-47.76%)
MNMD : 5.91 (+1.72%)
NUMIF : 0.0200 (-6.98%)
NUMI.TO : 0.0250 (-16.67%)
Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031

/PRNewswire/ -- Psychedelic and hallucinogenic medicines market have been growing consistently over the past several years and are expected to continue to rise...

NUMI.TO : 0.0250 (-16.67%)
CYBN : 9.68 (-1.43%)
CMPS : 5.94 (-2.94%)
MNMD : 5.91 (+1.72%)
SEEL : 1.28 (-47.76%)
NUMIF : 0.0200 (-6.98%)
Cybin Announces Phase 2 Cohort 5 Dosing Completion of CYB003 in Major Depressive Disorder

/CNW/ - Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) ("Cybin"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by...

CYBN : 9.68 (-1.43%)
Cybin to Participate at the 26th Annual Milken Institute Global Conference

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative...

CYBN.NE : 13.3400 (-0.45%)
CYBN : 9.68 (-1.43%)
Cybin Announces EMBARK Open Access, the First Free Online Course Providing Facilitator Training for Psychedelic Therapy

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative...

CYBN.NE : 13.3400 (-0.45%)
CYBN : 9.68 (-1.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Cybin Inc. is a biotechnology company. It is focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin Inc. is based in Toronto, Canada.

See More

Key Turning Points

3rd Resistance Point 9.95
2nd Resistance Point 9.84
1st Resistance Point 9.76
Last Price 9.68
1st Support Level 9.57
2nd Support Level 9.46
3rd Support Level 9.38

See More

52-Week High 28.04
Fibonacci 61.8% 19.81
Fibonacci 50% 17.27
Fibonacci 38.2% 14.73
Last Price 9.68
52-Week Low 6.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar